Table 1 Case distribution
Clinical characteristics | MMR-deficient LS-associated N = 20 (%) | MMR-deficient MLH1-hypermethylated N = 20 (%) | MMR-intact N = 20 (%) | p value |
|---|---|---|---|---|
Age at diagnosis, mean (SD) | 58.4 (11.1) | 67.9 (8.6) | 65.2 (10.8) | p = 0.63 |
Stage | p = 0.52 | |||
IA | 15 (75) | 10 (50) | 15 (75) | |
IB | 2 (10) | 6 (30) | 3 (15) | |
II | 0 (0) | 1 (5) | 0 (0) | |
IIIA | 1 (5) | 0 (0) | 0 (0) | |
IIIB | 0 (0) | 1 (5) | 0 (0) | |
IIIC1 | 1 (5) | 1 (5) | 2 (10) | |
IIIC2 | 1 (5) | 1 (5) | 0 (0) | |
Grade | p = 0.06 | |||
1 | 11 (55) | 4 (20) | 9 (45) | |
2 | 2 (10) | 10 (50) | 7 (35) | |
3* | 7 (35) | 6 (30) | 4 (20) | |
Adjuvant treatment | p = 0.60 | |||
Surveillance | 12 (60) | 9 (45) | 8 (40) | |
Vaginal cuff brachytherapy | 6 (30) | 7 (35) | 8 (40) | |
Vaginal cuff brachytherapy and chemotherapy | 1 (5) | 0 (0) | 0 (0) | |
Chemotherapy | 0 (0) | 1 (5) | 1 (5) | |
Chemotherapy and pelvic radiation | 1 (5) | 2 (10) | 0 (0) | |
Pelvic radiation | 0 (0) | 1 (5) | 2 (10) | |
Hormones | 0 (0) | 0 (0) | 1 (5) | |
Recurrence | p = 0.43 | |||
Yes | 1 (5) | 1 (5) | 3 (15) | |
No | 18 (90) | 18 (90) | 14 (50) | |
Unknown | 1 (5) | 1 (5) | 3 (15) | |
Vital status | p = 0.18 | |||
Alive, NED | 17 (85) | 20 (100) | 16 (80) | |
Alive with disease | 1 (5) | 0 (0) | 0 (0) | |
Alive, unknown disease | 1 (5) | 0 (0) | 0 (0) | |
Dead with disease | 0 (0) | 0 (0) | 3 (15) | |
Dead, unknown disease | 1 (5) | 0 (0) | 1 (5) |
